When codeine became a prescription only drug in 2018, the number of overdoses dropped, our new research shows. But restricting sales of codeine is only one way to reduce harm from opioids.
Academic rigour, journalistic flair
Articles on Prescription drugs
Displaying 21 - 40 of 70 articles
The 1964 report that paved the way for Canada’s medicare envisaged that after universal coverage for doctors, the next step would be prescription drugs. But that next step hasn’t come.
Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
Three-quarters of people with an intellectual disability receive prescribed drugs.
The collective public health of Canada, the United States and Mexico will take a hit if the new NAFTA becomes law.
Health Canada must be unbiased and it must be seen to be unbiased – so that Canadians get the best possible value out of prescription drugs.
Alarming rise in deaths from two prescription drugs sees them reclassified as class C.
A new study reveals how many patient groups lobby for new drugs to be funded by public plans in Canada – all while receiving funding from the companies manufacturing the drugs in question.
It takes about three years for safety problems to be identified in new drugs, newer drugs are almost always more expensive, and yet Canadian doctors still hand out hundreds of thousands of samples.
Two community pharmacists suggest a way for improving the palatability of evidence-based universal pharmacare – for those working in health insurance, pharmacy and the pharmaceutical industry.
Buyers think you can tell the purity of a substance by looking at on an app – evidence shows they’re mistaken.
Insurance companies sometimes try to cut costs by substituting less expensive drugs for a specific drug prescription. That’s raising problems in many cases, and actually causing harm.
Shortages and high prices are making pharmaceuticals, often including generics, out of reach for millions of Americans.
The medication landscape is complicated and error-riddled, with very few care providers knowing all the drugs you are taking. Here’s how pharmacists could be the solution.
As Canadians consider possibilities for pharmacare reform in the coming months, they should have access to the best available evidence about how it might work in our country.
The strengths of blockchain technologies could help address the weaknesses of health care systems to store and secure medical records.
Big Pharma in Canada is far behind the curve when it comes to disclosing what payments to health-care professionals are for.
The Canadian government must undertake regular analysis of the drug shortage problem, if we are ever to develop sustainable solutions.
The logic behind U.S. president Donald Trump’s proposal that Canada and other countries have been “free-riding” off high prices in the United States is bizarre at best.
Current guidance is not leading to cost-effective practice.
Top contributors
-
Joel Lexchin is a Friend of The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of Health Law and Bioethics, Case Western Reserve University
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Associate Professor of Public Health, Texas A&M University
-
Associate Professor, Political Science, McMaster University
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Honorary Fellow, Department of Health Sciences, University of York
-
Associate Professor in Public Health, La Trobe University
-
Assistant Professor, Johns Hopkins University
-
Enterprise Fellow, University of South Australia
-
Assistant Professor of Emergency Medicine, MedStar Washington Health Center
-
Associate Professor of Public Health and Community Medicine; Weiner Hailey Family Professor, Tufts University
-
Director of Health Policy, USC Schaeffer Center, and Associate Professor, University of Southern California
-
Associate Professor of Sociology, Bentley University
